Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2
Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.
Inclusion Criteria:
Exclusion Criteria:
Kurume-shi, Fukuoka 830-0011, Japan
Takasaki-shi, Gunma 370-0829, Japan
Fukuyama-shi, Hiroshima 720-8520, Japan
Fukuyama-shi, Hiroshima 721-8511, Japan
Nishinomiya-shi, Hyōgo 663-8501, Japan
Osaka, Osaka 550-0006, Japan
Takatsuki -shi, Osaka 569-8686, Japan
Kawagoe-shi, Saitama 350-8550, Japan
Komae-shi, Tokyo 201-8601, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Chuo-shi, Yamanashi 409-3898, Japan
Amagasaki, Hyogo, 661-0012, Japan
Asahikawa-shi, 070-8610, Japan
Habikino-osaka, 583-0872, Japan
Higashiibaraki-gun, 311-3117, Japan
Higashiomi, Shiga, 521-1223, Japan
Iruma-gun, 350-0451, Japan
Kashiwa-shi, 277-0004, Japan
Kishiwada, Osaka, 596-0042, Japan
Konan-shi, 483-8704, Japan
Kure, Hiroshima, 737-0023, Japan
Kuroishi-aomori, 036-0541, Japan
Moriguchi-shi, 570-0096, Japan
Nagoya-aichi, 460-0001, Japan
Shiogama-miyagi, 985-0024, Japan
Suita-osaka, 564-0082, Japan
Takaraduka, 665-0881, Japan
Togane, Chiba, 283-0826, Japan
TSU, MIE, 514-0062, Japan
Yatomi-shi, 498-0017, Japan
Yatsushiro-shi, Japan
Yufu-shi, 879-5503, Japan